Stanford

Deepu Madduri

Adjunct Clinical Assistant Professor, Medicine - Blood & Marrow Transplantation

CLINICAL OFFICE (PRIMARY)

- **Stanford Health Care**

  300 Pasteur Dr

  Palo Alto, CA 94304

  Tel (650) 498-6000 **Fax** (650) 725-8950

Bio

CLINICAL FOCUS

- Hematology

PROFESSIONAL EDUCATION

- Board Certification: Hematology, American Board of Internal Medicine (2024)
- Board Certification: Medical Oncology, American Board of Internal Medicine (2024)
- Fellowship: Stanford Medicine Stem Cell Transplantation Fellowship (2014) CA
- Fellowship: Harbor-UCLA Medical Center Hematology/Oncology Fellowship (2013) CA
- Residency: St Mary Medical Center Internal Medicine Residency (2010) CA
- Medical Education: University of Oklahoma Health Sciences Ctr Registrar (2007) OK

Publications

PUBLICATIONS

- **Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.** *Nature medicine*
  Lin, Y., Raje, N. S., Berdeja, J. G., Siegel, D. S., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Massaro, M., Petrocca, F., Yeri, A., Finney, et al
  2023

- **Efficacy and Safety of Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 Subgroup Analysis**
  Jakubowiak, A., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., Hari, P., Schecter, J. M., Madduri, D., Yeh, T., Olyslager, Y., Banerjee, A., Jackson, C. C., Allred, et al
  AMER SOC HEMATOLOGY.2021

- **Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation AntigenDirected Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma**
  Martin, T., Usmani, S. Z., Berdeja, J. G., Jakubowiak, A., Agha, M., Cohen, A. D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., Munshi, N. C., O'Donnell, et al
  AMER SOC HEMATOLOGY.2021

- **Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study (vol 398, pg 314, 2021)** *LANCET*
  Berdeja, J. G., Madduri, D., Usmani, S. Z.

2021; 398 (10307): 1216

- **Incidence, mitigation, and management of neurologic adverse events in CARTITUDE-2, a phase 2 study of ciltacabtagene autoleucel (cilta-cel) in patients with Multiple Myeloma**

  Einsele, H., Parekh, S., Madduri, D., Santomasso, B., Gallego Perez-Larraya, J., van de Donk, N. J., Arnulf, B., Mateos, M., De Braganca, K. C., Varsos, H., Carrasco-Alfonso, M. J., Akram, M., Lendvai, et al

  CIG MEDIA GROUP, LP.2021: S120-S121

- **Efficacy and safety of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with progressive multiple myeloma after 1-3 prior lines of therapy: Initial results from CARTITUDE-2**

  Cohen, A., Agha, M., Madduri, D., Cohen, Y., Delforge, M., Hillengass, J., Goldschmidt, H., Weisel, K., Raab, M., Scheid, C., Schecter, J. M., De Braganca, K. C., Varsos, et al

  CIG MEDIA GROUP, LP.2021: S15

- **Updated results from CARTITUDE-1: Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T (CAR-T) cell therapy, in relapsed/refractory multiple myeloma (RRMM)**

  Jagannath, S., Berdeja, J. G., Jakubowiak, A., Agha, M., Cohen, A., Madduri, D., Hari, P., Yeh, T., Olyslager, Y., Banerjee, A., Jackson, C. C., Allred, A., Zudaire, et al

  CIG MEDIA GROUP, LP.2021: S15-S16

- **Incidence, Mitigation, and Management of Neurologic Adverse Events in the CARTITUDE-2 Study of Patients with Multiple Myeloma Treated with Ciltacabtagene Autoleucel (Cilta-Cel)**

  Jakubowiak, A., Parekh, S., Madduri, D., Santomasso, B., Gallego Perez-Larraya, J., van de Donk, N. J., Arnulf, B., Mateos, M., De Braganca, K. C., Varsos, H., Carrasco-Alfonso, M. J., Akram, M., Lendvai, et al

  CIG MEDIA GROUP, LP.2021: S421-S422

- **Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study** *LANCET*

  Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A., Hari, P., Htut, M., Lesokhin, A., Deol, A., Munshi, N. C., O'Donnell, et al

  2021; 398 (10297): 314-324

- **Incidence, mitigation, and management of neurologic adverse events in patients with multiple myeloma (MM) treated with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-2.**

  Einsele, H., Parekh, S. S., Madduri, D., Santomasso, B., De larraya, J., van de Donk, N. J., Arnulf, B., Mateos, M., De Braganca, K. C., Varsos, H., Carrasco-Alfonso, M., Akram, M., Lendvai, et al

  LIPPINCOTT WILLIAMS & WILKINS.2021

- **Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/ refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.**

  Usmani, S., Berdeja, J. G., Madduri, D., Jakubowiak, A. J., Agha, M. E., Cohen, A. D., Hari, P., Yeh, T., Olyslager, Y., Banerjee, A., Jackson, C., Allred, A., Zudaire, et al

  LIPPINCOTT WILLIAMS & WILKINS.2021

- **CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.**

  Agha, M. E., Cohen, A. D., Madduri, D., Cohen, Y. C., Delforge, M., Hillengass, J., Goldschmidt, H., Weisel, K., Raab, M., Scheid, C., Schecter, J., De Braganca, K. C., Varsos, et al

  LIPPINCOTT WILLIAMS & WILKINS.2021

- **CARTITUDE-1: Phase 1b/2 study of ciltacabtagene autoleucel in relapsed/Refractory multiple myeloma**

  Madduri, D., Berdeja, J., Usmani, S., Jakubowiak, A., Agha, M., Cohen, A., Stewart, A., Hari, P., Htut, M., O'Donnell, E., Munshi, N., Avigan, D., Deol, et al

  WILEY.2021: 16-17

- **SAFETY AND MANAGEMENT OF ADVERSE EVENTS WITH CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL RESULTS FROM CARTITUDE-1**

  Florendo, E., Wilmoth, J., Romanov, V., Garrett, A., Martin, T., Madduri, D.

  ONCOLOGY NURSING SOC.2021

- **Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma** *NEW ENGLAND JOURNAL OF MEDICINE*

  Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., Lam, L., Morgan, R. A., Friedman, et al

2019; 380 (18): 1726–37

- **Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.** *The New England journal of medicine*

  Raje, N. n., Berdeja, J. n., Lin, Y. n., Siegel, D. n., Jagannath, S. n., Madduri, D. n., Liedtke, M. n., Rosenblatt, J. n., Maus, M. V., Turka, A. n., Lam, L. P., Morgan, R. A., Friedman, et al

  2019; 380 (18): 1726–37

- **bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study.**

  Raje, N. S., Berdeja, J. G., Lin, Y., Munshi, N. C., Samuel, D., Siegel, D., Liedtke, M., Jagannath, S., Madduri, D., Rosenblatt, J., Maus, M., Turka, A., Lam, et al

  AMER SOC CLINICAL ONCOLOGY.2018

- **Association of high baseline ferritin with tocilizumab administration for CRS in relapsed/refractory multiple myeloma patients treated with bb2121 anti-BCMA CAR T cells**

  Berdeja, J. G., Lin, Y., Kochenderfer, J., Raje, N. S., Munshi, N. C., Siegel, D., Liedtke, M., Madduri, D., Rosenblatt, J., Maus, M., Turka, A., Lam, L., Hege, et al

  AMER SOC CLINICAL ONCOLOGY.2018

- **Early MRD negativity to predict deepening myeloma response in relapsed/refractory multiple myeloma (RRMM) patients treated with bb2121 anti-BCMA CAR T cells.**

  Munshi, N. C., Berdeja, J. G., Lin, Y., Kochenderfer, J., Raje, N. S., Liedtke, M., Jagannath, S., Madduri, D., Rosenblatt, J., Maus, M., Turka, A., Lam, L., Hege, et al

  AMER SOC CLINICAL ONCOLOGY.2018